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Abstract Childhood renal osteodystrophy (ROD) is the
consequence of disturbances of the calcium-regulating
hormones vitamin D and parathyroid hormone (PTH) as
well as of the somatotroph hormone axis associated with
local modulation of bone and growth cartilage function.
The resulting growth retardation and the potentially rapid
onset of ROD in children are different from ROD in
adults. The biochemical changes of ROD as well as its
prevention and treatment affect calcium and phosphorus
homeostasis and are directly associated with the devel-
opment of cardiovascular disease in pediatric renal pa-
tients. The aims of the clinical and biochemical surveil-
lance of pediatric patients with CRF or on dialysis are
prevention of hyperphosphatemia, avoidance of hyper-
calcemia and keeping the calcium phosphorus product
below 5 mmol
2/l
2. The PTH levels should be within the
normal range in chronic renal failure (CRF) and up to 2–3
times the upper limit of normal levels in dialysed chil-
dren. Prevention of ROD is expected to result in improved
growth and less vascular calcification.
Keywords Chronic renal failure · Secondary hyperpara-
thyroidism · Calcium-phosphate product · Vitamin D ·
Parathyroidectomy
Introduction
Chronic renal failure is associated with specific abnor-
malities of skeletal homeostasis, commonly called renal
osteodystrophy (ROD), which if not treated appropriately
during the critical phases of skeletal growth can result in
bone deformities and a disturbed growth pattern. The
main factors for the development of ROD are distur-
bances in the calcium phosphate homeostasis, in vitamin
D and parathyroid hormone metabolism as well as alter-
ations in the somatotroph axis, i.e., on the endocrine and
paracrine levels. In recent years it has been recognized
that the spectrum of renal bone disease covers ‘high-’ as
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Fax: +49-6421-2865427well as ‘low-turnover’ conditions. As a consequence of
chronic renal failure itself and of the treatment of renal
bone disease, high plasma phosphate levels and an ele-
vated calcium phosphorus product are common. These are
important risk factors for the development of vascular
calcification and cardiovascular morbidity and mortality
in young adults who have been on renal replacement
therapy since childhood [1, 2]. Because aluminium-con-
taining phosphate binders are no longer indicated in
children, aluminium-related osteopathy is not considered
in these recommendations.
The European Pediatric Peritoneal Working Group
(EPPWG) was established in 1999 by pediatric nephrol-
ogists with a major interest in peritoneal dialysis and has,
among others, published guidelines on chronic and acute
peritoneal dialysis [3, 4, 5, 6]. The group incorporates
pediatric nephrologists from 12 European countries. One
of the functions of the group is to establish expert guid-
ance in important clinical areas associated with chronic
renal failure and dialysis [now the European Pediatric
Dialysis Working Group (EPDWG)] in conjunction with
other members of the multidisciplinary team. These
guidelines were initiated and discussed at meetings of the
group and developed by e-mail discussion to develop
consensus of opinion based upon cumulative clinical ex-
perience and reported studies.
Recommendations
Recommendation 1
Clinical, biochemical and radiological markers of re-
nal bone disease should be monitored regularly. The
clinical markers of renal bone disease to be prevented are
signs of overt rickets, slipped femoral epiphysis and dis-
turbances of growth. The biochemical markers are plasma
phosphate, calcium, alkaline phosphatase, bicarbonate
and intact parathyroid hormone (PTH). The minimal
frequency of measurements (and target ranges) for bio-
chemical markers in a stable phase vary according to
renal function (Table 1). If the patient has active ROD,
additional blood samples may be required.
Plasma calcium must be adjusted for albumin levels (=
corrected calcium) or by measuring ionized (free) calci-
um, in patients with hypoalbuminemia or acid-base dis-
orders. Ionized calcium values are often available on
blood gas analysis systems with calcium-sensitive elec-
trodes, but correct values are only obtained in validated
conditions. Alkaline phosphatase as a marker for osteo-
blast activity has particular importance in both low and
high-turnover bone disease with elevated or low alkaline
phosphatase serum levels, respectively.
PTH should be monitored monthly in advanced CRF
(GFR <15 ml/min/1.73m
2) because of its rapid changes.
Different assays are available for the measurement of
PTH. In principle, intact PTH(1–84) (iPTH) should be
measured because it is believed to represent the active
hormone. For this purpose, two-site assays were developed
at the end of the 1980s [7]. However, PTH fragments
accumulating in end-stage renal disease may also show
biological activity. Furthermore, recent research using
plasma samples from healthy and renal patients analyzed
by HPLC and the iPTH assay demonstrated cross-reac-
tivity of the intact PTH-assay with a PTH-fragment
(PTH7–84). Therefore, new assays were developed that
detect only PTH molecules with a complete N-terminal
end, called “whole-PTH” assays [8]. In adult and pediatric
dialysis patients, these “whole PTH” assays yielded 30–
60% lower PTH levels than the intact PTH assay. Despite
theoretical considerations, no significant improvement in
the distinction between the different forms of renal bone
disease using the “whole PTH” assays has yet been
demonstrated in clinical practice [9, 10, 11, 12].
Table 1 Frequency of measurements for biochemical and radiological markers of renal osteodystrophy
Marker
1 Frequency of measurement (every x month) Target
GFR GFR GFR <15, dialysis
59–30 29–15 (Evidence)
Calcium or 6 3 1 Normal range (corrected calcium)
2
Ionized calcium Normal range
2
Phosphate 6 3 1 Normal range for age band
Calcium phosphorus
product
63 1 5.0 mmol
2/l
2
Target range 3.3–4.4 mmol
2/l
2, 3
Alkaline phosphatase 6 3 1 Normal range for age band
Serum bicarbonate/
base excess
6 3 1 Normal range, at least: bicarbonate >22 mmol/l
Base excess > 5 mmol/l
Intact PTH/whole PTH 6 3 1 Normal range in moderate CRF
(GFR>29 ml/min/1.73m
2)
Up to 2–3 times upper limit of normal
in advanced CRF or on dialysis




Left hand and wrist X-ray 6–12 No radiological signs of hyperparathyroidism
No Looser zones or osteopenia






calcium (mg/dl) = measured calcium concentration (mg/dl) + 0.8   [4-measured albumin concentration (g/dl)]; corrected calcium (mmol/l)
= measured calcium concentration (mmol/l) +0.2   [4-measured albumin concentration (g/dl)].
3 Depending on age.
4Only in patients with
suspected vitamin D deficiency
152Radiological signs of renal bone disease, which alone
are not sensitive enough to indicate therapy-adaptations,
include signs of hyperparathyroidism and growth zone
lesions. Periosteal resorption zones and metaphyseal
changes are the most obvious signs. In late adolescent and
young adult patients, Looser zones as specific signs of
osteomalacia may be found. The sites and expression of
bone lesions are age-dependent according to the age-de-
pendent growth and remodeling at different sites of the
skeleton. In pre-school children, the metaphysis of the
distal radius and ulna may present only minor abnor-
malities, whereas more severe lesions may be seen at the
upper and lower femoral epiphysis. Adynamic bone dis-
ease shows no specific radiological changes. However,
extraosseous calcifications, fractures or osteopenia may
indicate adynamic bone disease.
Histological evaluation of bone biopsy specimens re-
main the “gold standard” in assessment of renal osteo-
dystrophy. However, due to its invasive nature, bone
biopsies are not performed in clinical practice, but they
remain an important tool for research [12].
Recommendation 2
Metabolic acidosis should be corrected (evidence).
Chronic metabolic acidosis leads to increased bone re-
sorption and inhibits endochondral bone formation in
animal experiments [13, 14]. Infants with isolated chronic
metabolic acidosis show growth retardation [14]. In adult
hemodialysis patients, negative aspects of chronic meta-
bolic acidosis on metabolism have been reported [15].
Therefore, metabolic acidosis should be corrected by a
stepwise approach: The first step is optimization of the
dialysis regimen both for HD- and PD-patients [4, 15].
Since the introduction of HCO3-based PD solutions [16],
metabolic acidosis is a less frequent problem. In combi-
nation with a daytime-dwell, patients may even be at risk
for alkalosis [17]. However, if these adaptations do not
result in correction of the metabolic acidosis, sodium bi-
carbonate should be administered orally. Whenever pos-
sible, formulations that dissolve in the small intestine
should be used. The use of sodium citrate increases the
risk of aluminium absorption [18, 19]. Acidosis should be
corrected to the normal range of the local laboratory.
Recommendation 3
The plasma-phosphate level should be kept within the
normal age-specific range (evidence). In children with
chronic renal failure, hyperphosphatemia is observed at
GFR levels below 40 ml/min/1.73m
2 [20] and almost
always in children on dialysis. Hyperhosphatemia has
several deleterious effects on PTH secretion [21, 22],
parathyroid cell proliferation [23] and soft tissue (vascu-
lar) calcification [1, 2].
Increased phosphate levels stimulate PTH secretion in
vitro [24] and in vivo [21, 25] independent of calcium and
1,25(OH)2 vitamin D3 levels. This effect of phosphate on
PTH secretion occurs via post-transcriptional processes
by regulating pre-pro-PTH mRNA stability [26]. Fur-
thermore, a reduction of serum-phosphate results in a
parallel reduction of PTH levels without change in serum
calcium [27]. Hyperphosphatemia accelerates parathyroid
cell proliferation [23], which can result in nodular hy-
perplasia and severe hyperparathyroid bone disease ne-
cessitating parathyroidectomy (see below).
Increased plasma phosphate levels have a profound
effect on soft tissue and vascular calcification, which are
often observed in young patients on or even after dialysis
[1, 2, 28], increasing the risk of cardiovascular morbidity
and mortality. Block et al. [29] found an increased risk of
death for serum phosphate exceeding 2.09 mmol/l in adult
patients; other studies described a much lower phosphate
level (~1.4–1.6 mmol/l) at which a higher incidence of
calcifications was found [1, 30, 31]. The histology of the
calcification pattern is quite distinct from the process of
atherosclerosis. In renal patients, extensive calcification
of the tunica media occurs even after short periods of
dialysis, as shown by investigations of the epigastric ar-
tery in adult patients [32]. Experimental work gave evi-
dence for an active role of phosphate in this process as
phosphate induces osteoblastic marker followed by cal-
cification in cultured smooth muscle cells [33]. Dialysis
patients are at risk of heart failure. Although this is a
multifactorial process, it was demonstrated in animal
experiments that high plasma phosphate levels per se
accelerated cardiac fibrosis [34].
Recommendation 4
If plasma phosphate is elevated, phosphate intake
should be limited to the recommended levels. Dietary
intake of protein and as a consequence of phosphate in
western countries usually exceeds the recommended in-
take at least in adolescent dialysis patients. Therefore,
dietary counseling should be performed by a trained di-
etician [35]. If the dietary records show a protein intake
above the recommended level for pediatric dialysis pa-
tients, the patients and their parents should be trained to
reduce their phosphate intake. This may start with the
reduction of dairy products and/or substitution with spe-
cial low-phosphorus products and a reduction of meat
intake.
Recommendation 5
In case of hyperphosphatemia, the dialysis efficacy
should be optimized (evidence). Phosphate is slowly
transported via the peritoneal membrane into the dialysate
[36]. The dialysate to plasma ratio (D/P) for phosphate is
volume and time related; after 4 h in standard peritoneal
equilibration tests, this ratio reaches the value of 0.5–0.6,
which is a much lower ratio than for urea, which is usu-
ally nearly 1. Therefore, an increase in phosphate removal
153should consider not only an increase in dwell volume to
1,000–1,400 ml/m
2 BSA, but also dwell time optimiza-
tion, avoiding a too short dwell time. A daytime dwell
should be added. The details of a dialysis regimen opti-
mization has been described elsewhere [5]. However, due
to the low clearance of phosphate achievable even with an
optimized PD regimen, dietary phosphate restriction and
the use of oral phosphate binders are almost always
necessary.
The dialytic phosphate removal kinetic during a he-
modialysis session differs from urea kinetic: after an early
initial drop the phosphatemia decrease only slowly [37,
38]. Therefore, it is admitted that the hemodialysis
phosphate purification capacity is directly impacted by
the duration of the dialysis session, because the phosphate
shift from the intracellular to the vascular compartment is
time-dependent. Therefore, longer dialysis sessions [39]
or daily dialysis sessions [40, 41, 42] offer a unique,
powerful dialysis method for optimal phosphate purifi-
cation. The hemodialysis modality, HD, HF or HDF, and
the type of the synthetic membrane used have only a
limited impact on dialytic phosphate removal [38],
whereas the dialysate composition in terms of glucose and
bicarbonate concentration are presumed to be of impor-
tance [42, 43, 44], modulating a shift of intracellular
phosphate trapped in the cells, where it is not available for
dialysis exchanges.
Recommendation 6
For control of hyperphosphatemia, aluminium-free
phosphate binders should be administered (evidence).
Phosphate binders are necessary to reduce phosphate ab-
sorption from the gut. Ca-containing phosphate binders,
i.e., calcium carbonate (CaCO3, elemental calcium con-
tent 40%) or calcium acetate (CaAc, elemental calcium
content 25%) should be used as the first line. No data are
published on the efficacy and safety of calcium acetate/
magnesium carbonate compound phosphate binders in
pediatric patients. The upper intake level of elemental
calcium is suggested to be 2,500 mg/day for healthy
children above 4 years of age [19]. Whereas for adult
dialysis patients the DOQI guidelines suggest to limit the
elemental calcium intake to 2,000 mg/day, no safe upper
level can be given for the pediatric age band. However, a
positive calcium balance in the range of +200–+300 mg in
the growing skeleton should be maintained. In contrast, a
too high calcium load should be avoided, because one of
the identified risk factors for soft tissue calcification in
pediatric CRI patients was cumulative calcium intake [2,
24].
Calcium-containing phosphate binders are started at
approximately 500 mg per 200 mg phosphate content of
the diet (0–1 years, 1–2 500 mg; 1–4 years, 2–3 500 mg/
day; 5–8 years, 3–4 500 mg/day; 9–18 years, 5 500 mg).
An alternative approach is a start dose of approximately
50 mg/kg/day, which is well below the doses given in
clinical studies. Phosphate binders are then adjusted to
normalize serum-phosphate and calcium. CaCO3 can be
crushed to fine powder, or a 10% solution can be used for
administration in infants, often via a feeding tube. The
phosphate binders should be taken with meals, because
fecal excretion of phosphate was higher when calcium
acetate was given with meals instead of in between meals
[45]. Biochemically, CaAc has a higher phosphate bind-
ing capacity, which is independent of the pH. The higher
efficacy of CaAc, calculated on a weight basis compared
to CaCO3, for phosphate control was also shown in
clinical practice in adult and pediatric patients [46, 47].
Unfortunately, compliance of the patients with the intake
of phosphate binders is often poor and should be checked
regularly. It may be helpful if the patient is involved in
selecting the flavor and size of the phosphate binder and
has regular contact with the dietician at clinic appoint-
ments. Snacks during the day are often a source of ad-
ditional phosphate and require additional phosphate bin-
ders.
Patients treated with Ca-containing phosphate binders
and active vitamin D metabolites are particularly at risk
for the development of hypercalcemia. Therefore, in case
of hypercalcemia, active vitamin D metabolites should be
stopped (see recommendation 12). If hypercalcemia, the
most common side-effect of Ca-containing phosphate
binder therapy, persists or the calcium phosphorus prod-
uct exceeds 5.0 mmol
2/l
2 with the use of Ca-containing
phosphate binders, the calcium content in the dialysis
fluid should be reduced [5]. Furthermore, the dose of the
calcium-containing phosphate binders should be reduced
whenever possible or they should be replaced by Ca- and
aluminium-free phosphate binders, because epidemio-
logical studies have shown a direct relationship between
serum phosphate and calcium phosphorus product on
mortality [29, 48]. The only commercially available alu-
minium- and calcium-free phosphate binder is Sevelamer.
This compound is usually taken orally as capsules, but
anecdotally can be delivered via enteral tubes by dis-
solving the capsule in 5 ml water (instruction Fa gen-
zyme). Aluminium-containing phosphate binders or cal-
cium citrate increase intestinal aluminium absorption and
should not be used in pediatric dialysis patients. An al-
ternative phosphate binder that is available is lanthanum
carbonate, which has a high affinity for phosphate, and is
minimally absorbed in the intestine. In a randomized
study in adult patients, lanthanum carbonate controlled
plasma phosphate levels well and induced less adynamic
bone disease than CaCO3 [49]. However, no long-term
data on the effect of lanthanum on bone, on which surface
lanthanum can accumulate [50], and its safety profile for
use in children are available yet.
Recommendation 7
Vitamin D deficiency should be avoided (evidence). In
early renal failure, an increase of PTH correlates posi-
tively with 25(OH)-vitamin D3 levels [51]. Renal syn-
thesis of 1,25(OH)2 D3 is impaired in chronic renal dis-
154ease. However, extrarenal cells, i.e., macrophages and
osteoblasts, are also capable of 1,25(OH)2 D3 production
[52]. In contrast to the kidney, the extra-renal synthesis is
strictly substrate dependent. It has been shown that sup-
plementation with vitamin D3 in elderly CRF patients
with 25(OH)-vitamin D3 levels between 20 and 50 pg/ml
decreased PTH serum concentrations [53]. Furthermore,
25-OH-vitamin D3, but not 1,25(OH)2 D3, improved
muscular function and phosphate content [54]. Therefore,
vitamin D deficiency should be prevented.
Recommendation 8
Marked hyperparathyroidism should be prevented in
children with CRF prior to dialysis (evidence). Due to
the risk of persisting bone disease and the development of
parathyroid adenoma, an increase in PTH above normal to
slightly elevated levels should be prevented in children
with CRF. Therefore, low doses of active vitamin D
metabolites should be given in time. In adult patients this
treatment regimen has resulted in controlled iPTH without
negative aspects [55]. In children with moderate renal
failure (GFR >30 ml/min/1.73 m
2), normal levels of PTH
in association with strictly controlled phosphate levels are
associated with a normal ratio of intact PTH to “whole”
PTH and normal levels of alkaline phosphatase, indicat-
ing a physiological PTH secretion and unremarkable bone
turnover [10]. In such patients, slight catch-up growth
with PTH levels at the upper limit of normal was reported
[56]. In a sub-group analysis, improved growth was re-
stricted to patients with enteral feeding tubes.
Recommendation 9
PTH levels should be kept at two to three times the
upper limit of the normal range in end-stage renal
disease (evidence). Grossly elevated PTH concentrations
(>four times the upper normal range) in the presence of
normal or high serum calcium and high alkaline phos-
phatase are almost always associated with high-turnover
bone disease [56, 57]. The exception is intermittent
therapy with high-dose active vitamin D metabolites,
because 1,25(OH)2 vitamin D3 directly inhibits osteo-
blastic function and proliferation. Hyperphosphatemia can
occur in hyperparathyroid bone disease because of ex-
cessive bone resorption.
However, in pediatric dialysis patients low and even
normal levels of PTH are reported to be associated with
low turnover bone disease [57]. A PTH concentration
higher than in healthy subjects is needed to stimulate bone
turnover due to resistance of the skeleton to PTH in ad-
vanced renal failure. If PTH falls into the (low) normal
range, the risk of hypercalcemia increases [58]. Hyper-
phosphatemia and hypercalcemia can develop in low
turnover bone disease because the skeleton is unable to
take up enough phosphate and calcium. Low bone turn-
over or adynamic bone disease is increasingly observed in
adult [59] as well as in pediatric PD patients [56]. Risk
factors for adynamic bone disease are high calcium intake
(Ca-containing phosphate binders), therapy with high
doses of active vitamin D metabolites, peritoneal dialysis
using dialysis fluid with high calcium content and age
(adolescents after the growth spurt). Biochemically, hy-
percalcemia and/or PTH levels within or below the nor-
mal range are indicative of low turnover bone disease [56,
58], which may adversely affect growth in dialysed
children [60]. Therefore, active vitamin D therapy should
be reduced or stopped if PTH falls below the low normal
range [57, 59, 61]. If PTH remains below normal despite
normal calcium and phosphate levels, the dialysate should
be changed to low calcium solutions (1.0 or 1.25 mmol/l)
to stimulate PTH secretion [61], if this is not already used
as the standard solution [5].
Recommendation 10
If PTH is elevated in children with CRF or if PTH is
elevated more than two to three times normal in the
presence of Pi <2 mmol/l in dialyzed children, active
vitamin D metabolites should be administered orally
(evidence). Treatment with active vitamin D metabolites
results in biochemical and/or histological improvement in
patients with high-turnover bone disease. Doses of
1,25(OH)2 vitamin D3 or 1a-(OH) vitamin D3 usually
range from 0.1  g/day to 0.75  g/day, with a starting dose
of 20–40 ng/kg. High doses often induce hypercalcemia,
necessitating the reduction or discontinuation of vitamin
D therapy (see hypercalcemia).
As to the mode of administration of the active vitamin
D metabolites, intravenous or oral therapy, have the same
efficacy [63]. Therefore, the oral route should be pre-
ferred in children on dialysis. Doses should be given in
the evening, because fewer episodes of hypercalcemia
have been reported compared to taking the vitamin D
metabolites in the morning [64]. Intermittent therapy was
shown to be effective to suppress elevated PTH serum
levels [59]. However, recent data indicate that large in-
termittent 1,25(OH)2 vitamin D3 doses adversely affect
bone turnover [57, 61, 65] and chondrocyte activity [66]
resulting in low turnover bone disease and in reduced
growth [65, 66, 67, 68]. In addition, episodes of hyper-
calcemia occur with similar frequency with the intermit-
tent or oral administration of vitamin D metabolites [63,
69]; furthermore, the intermittent mode of administration
was not shown to be more effective in suppressing PTH
levels in adult [70] and pediatric [63] patients in
prospective, randomized trials. For the above mentioned
reasons, intermittent high-dose vitamin D therapy should
be avoided in pediatric patients.
Three newer vitamin D analogs, so called “non-hy-
percalcemic” vitamin D analogs (doxercalciferol, pari-
calcitol and 22-oxa-calciferol), have been introduced in
clinical use in adult patients with secondary hyperpara-
thyroidism due to CRF. Despite their ability to induce less
hypercalcemia in animal experiments, only one clinical
155study with a head-to-head comparison of the new vitamin
D analogue (paricalcitol) is available demonstrating a
borderline reduction of hypercalcemia or a decrease in
calcium phosphorus product [71]. No data are available
for their use in children.
Agents that specifically enhance the sensitivity of the
calcium-sensing receptor, called calcimimetics, used in
combination with active vitamin D metabolites in adult
dialysis patients resulted in a persistent decrease of PTH
levels without elevated calcium phosphorus product [72].
If plasma Ca or Pi is high in the presence of elevated
PTH, the calcimimetics may become first choice. How-
ever, no data for pediatric patients are available.
Recommendation 11
Treatment with growth hormone should not be started
in the presence of severe hyperparathyroid bone dis-
ease. It is well established that the uremic growth retar-
dation is at least in part due to disturbed pulsatile secre-
tion of growth hormone as well as a peripheral growth
hormone resistance [73]. After correction of metabolic
acidosis and normalization of caloric intake, administra-
tion of recombinant human growth hormone increases
growth velocity resulting in catch-up growth and in im-
proved final height [74]. Growth hormone directly stim-
ulates growth cartilage proliferation and metabolism and
osteoblast activity [75, 76]. This growth promoting effect
of GH was suspected to increase the metaphyseal insta-
bility induced by severe hyperparathyroidism. In hyper-
parathyroid bone disease, i.e., osteitis fibrosa, a fibrous
layer is formed at the metaphyseal junction of the growth
plate with the bone tissue. This can lead to epiphyseal
slipping resulting in gross deformities of the affected long
bones [77]. Therefore, parathyroid hormone, as well as
calcium and phosphate levels, should be treated towards
the recommended normal ranges prior to administration
of GH. However, in a recent prospective study, no in-
creased frequency of epiphyseal slipping associated with
the use of growth hormone was reported [78]. After the
start of GH administration, an increase of PTH levels was
observed [79, 80].
Recommendation 12
In case of hypercalcemia, active vitamin D metabolites
and calcium-containing phosphate binders should be
stopped and dialysate changed to low calcium solu-
tions (evidence). Hypercalcemia and elevated calcium
phosphorus product (>5.0 mmol
2/l
2) should be corrected
promptly (Fig. 1). Vitamin D metabolites should be dis-
continued and in case of persisting hypercalcemia the
dialysate calcium decreased to low calcium dialysate.
Laboratory values should be controlled weekly until im-
provement is seen. One exception is hypercalcemia due to
severe hyperparathyroidism and high-turnover bone dis-
ease. In addition, in patients with residual renal function,
loop diuretics, i.e., furosemide may increase calcium ex-
cretion. If hypercalcemia is not corrected despite the
discontinuation of active vitamin D metabolites, calcium-
containing phosphate binders should be replaced by cal-
cium-free phosphate binders to reduce the calcium load.
Hypercalcemia is reported in up to 25% of patients taking
calcium-containing phosphate binders ([1, 29], see rec-
ommendation 6).
Recommendation 13
The calcium phosphorus product should be kept within





2) (evidence). One of the risk factors for cardiovascular
Fig. 1 Clinical algorithm for treatment of elevated calcium phosphorus product in children with CRF. Ca-cont calcium containing;
Ca-free calcium-free; phos-binder phosphate binder; vit D vitamin D; ADBD adynamic bone disease
156morbidity was shown to be an elevated calcium phos-
phorus product above 5.0 mmol
2/l
2 (see also recommen-
dation 2). If the calcium phosphorus product is elevated
above this level, phosphate and/or calcium levels should
be reduced. This may be achieved by an increase in
phosphate binders, reduction/stopping of active vitamin D




Parathyroidectomy has to be considered in case of severe,
therapy-refractory hyperparathyroidism with radiological
signs in combination with hypercalcemia and/or elevated
calcium phosphorus product (evidence). Severe hyper-
parathyroidism may no longer react to even high doses of
1,25(OH)2 vitamin D3 and reduction of phosphate levels.
The clinical observations in adults show that patients with
at least one parathyroid gland larger than 0.5 cm
3 or
1.0 cm in diameter usually do not respond to active vi-
tamin D metabolites [81, 82]. Therefore, persisting
grossly elevated PTH levels in the presence of high-dose
active vitamin D metabolites, radiological signs of hy-
perparathyroidism on wrist X-ray and/or high serum cal-
cium and normal phosphate and/or elevated calcium
phosphorus product indicate the need for surgical para-
thyroidectomy. Medical parathyroidectomy by alcohol
injection was described in adult patients [83], but to our
knowledge not in pediatric patients. Parathyroid hormone
stimulates bone turnover and regulates calcium homeo-
stasis, both of which are of utmost importance in the
growing skeleton. Therefore, subtotal parathyroidectomy
or autotransplantation of parathyroid tissue is recom-
mended in children or adolescents, avoiding hypopar-
athyroidism ([84], review). However, these procedures
carry the risk of recurrence of severe parathyroid tissue
hyperplasia. The use of the new calcimimetic agents [85]
may help to prevent the most severe hyperparathyroidism
and therefore modify the approach to that condition.
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